Skip to main content

Atopic Dermatitis Topic Center

Featured

Peter Lio
Clinical Insights
01/20/2026
Peter Lio, MD, FAAD
Dr Peter Lio discusses how urbanization, modern lifestyles, and shifting environmental exposures may be driving rising rates of allergic rhinitis, food allergy, and atopic dermatitis—and which exposures should most concern clinicians.
Dr Peter Lio discusses how urbanization, modern lifestyles, and shifting environmental exposures may be driving rising rates of allergic rhinitis, food allergy, and atopic dermatitis—and which exposures should most concern clinicians.
Dr Peter Lio discusses how...
01/20/2026
Allergy & Immunology
Comorbidities
12/06/2025
Rebecca Mashaw
A large pooled analysis finds significantly elevated autoimmune disease risk among patients with atopic dermatitis.
A large pooled analysis finds significantly elevated autoimmune disease risk among patients with atopic dermatitis.
A large pooled analysis finds...
12/06/2025
Allergy & Immunology
News
11/17/2025
Rebecca Mashaw
The expanding portfolio of atopic dermatitis therapies underscores a pivotal transition from suboptimal traditional treatments toward safer, more individualized care across age groups.
The expanding portfolio of atopic dermatitis therapies underscores a pivotal transition from suboptimal traditional treatments toward safer, more individualized care across age groups.
The expanding portfolio of...
11/17/2025
Allergy & Immunology
Research Highlights
11/17/2025
Rebecca Mashaw
Recent research highlighted the relationship between atopic dermatitis and food allergy in children with a focus on shared mechanisms, clinical implications, and treatment approaches.
Recent research highlighted the relationship between atopic dermatitis and food allergy in children with a focus on shared mechanisms, clinical implications, and treatment approaches.
Recent research highlighted the...
11/17/2025
Allergy & Immunology
Therapeutic Advances
11/17/2025
Rebecca Mashaw
For clinicians, understanding the interplay between lipid barrier defects, microbial dysbiosis, and immune dysregulation is critical to guiding therapy.
For clinicians, understanding the interplay between lipid barrier defects, microbial dysbiosis, and immune dysregulation is critical to guiding therapy.
For clinicians, understanding...
11/17/2025
Allergy & Immunology
Atopic dermatitis
FDA Alerts
10/06/2025
Riya Gandhi, MA
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA...
10/06/2025
The Dermatologist
From The Dermatologist